Key result
The PDE3 inhibitor cilostamide potentiated the positive inotropic effects of adrenaline (0.78 ± 0.12 log units) more than noradrenaline (0.47 ± 0.12 log units) in metoprolol-treated failing hearts (P=0.037).
Population
Right and left ventricular trabeculae from freshly explanted hearts of 20 patients with terminal heart…
Comparison
PDE3-selective inhibitor cilostamide or PDE4… vs Absence of PDE inhibitors.
Design
Preclinical
Authors
Loading...
May indicate selective adrenaline potentiation by PDE3 inhibition in failing hearts; hypothesis-generating for in vivo effects during beta-blockade.
Effect estimate: 0.78 ± 0.12 log units for adrenaline vs 0.47 ± 0.12 log units for noradrenaline
p-value: p=0.037
In failing human ventricles from metoprolol-treated patients, PDE3 (but not PDE4) inhibition potentiates the inotropic and lusitropic effects of catecholamines, particularly adrenaline.
Molenaar et al. (2013) studied terminal heart failure (n=20). Cilostamide and Rolipram vs. Absence of PDE inhibitors was evaluated on Potentiation of positive inotropic effects of catecholamines (0.78 ± 0.12 log units for adrenaline vs 0.47 ± 0.12 log units for noradrenaline, p=0.037). The PDE3 inhibitor cilostamide potentiated the positive inotropic effects of adrenaline (0.78 ± 0.12 log units) more than noradrenaline (0.47 ± 0.12 log units) in metoprolol-treated failing hearts (P=0.037).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: